Literature DB >> 7525994

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

W J Catalona1, J P Richie, J B deKernion, F R Ahmann, T L Ratliff, B L Dalkin, L R Kavoussi, M T MacFarlane, P C Southwick.   

Abstract

We present the results of a prospective multicenter clinical trial of nearly 5,000 men in which prostate specific antigen (PSA) density was compared to the serum PSA concentration alone for early detection of prostate cancer. All men were evaluated with PSA and digital rectal examination. If PSA was elevated (greater than 4 ng./ml., Hybritech Tandem assay) or digital rectal examination was suspicious, transrectal ultrasound guided biopsies were recommended. Prostate volume was estimated by transrectal ultrasound measurements using a prolate ellipse volume calculation and PSA density was calculated by dividing serum PSA concentration by gland volume. Using a PSA density cutoff of 0.15 as recommended in the literature enhanced specificity but at the cost of missing half of the tumors. Of the organ confined neoplasms 47% were detected by a PSA of greater than 4.0 ng./ml. but they were missed by a PSA density of more than 0.15. PSA density may not be predictive for cancer because accurate estimation of transrectal ultrasound volume is difficult (r = 0.61 for estimated transrectal ultrasound volume versus pathological prostate weight). However, a relationship does exist among transrectal ultrasound volume, PSA and positive predictive value for cancer. PSA concentrations of less than 4.0 ng./ml. did not indicate a need for biopsy (positive predictive value 12 to 17%) unless the digital rectal examination findings were suspicious for cancer. A high percentage of patients with a PSA of more than 10 ng./ml. had cancer (30 to 75%), regardless of gland size. Patients with intermediate PSA concentrations (4.1 to 9.9 ng./ml.) and a gland size of 50 cc or less had a 35 to 51% positive predictive value, while those with intermediate PSA concentrations and a large gland (more than 50 cc) had a 15% positive predictive value. We conclude that in men with a PSA level of 4.1 to 9.9 ng./ml., and normal digital rectal examination and transrectal ultrasound findings, the use of a PSA density cutoff of more than 0.15 for biopsy results in half of the tumors being missed. Thus, we recommend that men in this group undergo biopsy based upon serum PSA concentration rather than PSA density.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525994     DOI: 10.1016/s0022-5347(17)32299-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  40 in total

Review 1.  The role of prostate specific antigen in screening and management of clinically localized prostate cancer.

Authors:  Khurshid Guru; Ashutosh Tewari; Ashok K Hemal; John Wei; Javid Javidan; James Peabody; Mani Menon
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

2.  Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Guangyun Sun; Ritesh Kaushal; Joshua J Meeks; C Shad Thaxton; Saurav Guha; Carol H Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2007-06-26       Impact factor: 4.132

3.  Variability of assay methods for total and free PSA after WHO standardization.

Authors:  L Foj; X Filella; J Alcover; J M Augé; J M Escudero; R Molina
Journal:  Tumour Biol       Date:  2013-10-04

4.  Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.

Authors:  M Sheikh; O Al-Saeed; E O Kehinde; T Sinan; J T Anim; Y Ali
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 5.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

6.  Latest tests for prostatic neoplasia.

Authors:  W J Marshall
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

7.  Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.

Authors:  Findlay MacAskill; Su-Min Lee; David Eldred-Evans; Wahyu Wulaningsih; Rick Popert; Konrad Wolfe; Mieke Van Hemelrijck; Giles Rottenberg; Sidath H Liyanage; Peter Acher
Journal:  Int Urol Nephrol       Date:  2017-05-05       Impact factor: 2.370

8.  Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study.

Authors:  Yejin Mok; Heejin Kimm; Sang Yop Shin; Sun Ha Jee; Elizabeth A Platz
Journal:  Urology       Date:  2015-05       Impact factor: 2.649

Review 9.  Prostate cancer: diagnosis and staging.

Authors:  Nigel Borley; Mark R Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  Accuracy of a high prostate-specific antigen level for prostate cancer diagnosis upon initial biopsy in Korean men.

Authors:  Hong Bang Shim; Sang Eun Lee; Hyoung Keun Park; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.